scholarly journals Rheumatoid arthritis and the challenge of using nanoparticles for its treatment

2018 ◽  
Vol 154 ◽  
pp. 04005 ◽  
Author(s):  
Lutfi Chabib ◽  
Zullies Ikawati ◽  
Ronny Martien ◽  
Hilda Ismail ◽  
Made Dwi Pradipta Wahyudi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Clinical Manifestation ◽  
Side Effect ◽  
Clinical Manifestations ◽  
Rheumatoid Arthritis Treatment ◽  
Effective Role

Rheumatoid arthritis is the most common autoimmune disease that affects the joints. The cause of the disease is unknown, many studies proposed hypothesis about the etiology of rheumatoid arthritis. The clinical manifestations of arthritis are different in each patients. In addition, the development of the medication is still continue to achieve the most effective role with less side effect. Nanoparticles may be the answer to this problem, since they have been widely used to improve the pharmacokinetic and pharmacodynamics of rheumatoid arthritis drugs. Using nanoparticles-tagged folate or PEG to deliver rheumatoid arthritis drugs may increase the specificity of the drugs to the target and consequently, may decrease the side effects of the drugs. The purpose of this review is to summarize the etiology, clinical manifestation and highlighting the use of nanoparticles in rheumatoid arthritis treatment.

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

2020 ◽  
Vol 26 ◽  
Author(s):  
Ritu Mishra ◽  
Swati Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Autoimmune Disease ◽  
Drug Delivery Systems ◽  
Clinical Manifestations ◽  
Adaptive Immune Response ◽  
Delivery Systems ◽  
Current Therapy ◽  
Genetic And Environmental Factors ◽  
Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

Dermal Discoloration Secondary to Triamcinolone Acetonide Injection Observed in Patients with Autoimmune Disorders

2021 ◽  
Vol 111 (4) ◽  
Author(s):  
James A. Wright ◽  
Jessica A. Wenz ◽  
Gabrielle Jackson Madrigal
Keyword(s):  
Psoriatic Arthritis ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Triamcinolone Acetonide ◽  
Current Literature ◽  
Side Effect ◽  
Inflammatory Conditions ◽  
Rare Side Effect ◽  
History Of ◽  
Synthetic Glucocorticoid

Triamcinolone acetonide is a synthetic glucocorticoid used to treat numerous acute and chronic inflammatory conditions. The various side effects of this drug from parenteral administration are well documented in the literature. In this study, three patients present with a rare side effect of violaceous dermal pigmentation. To the best of the authors' knowledge, this finding is rarely presented in the current literature. The purpose of this study is to provide awareness of a less-documented, delayed side effect from triamcinolone acetonide administration. Although all patients presenting in this study had a known history of autoimmune disease (eg, lupus, psoriatic arthritis) further research is needed to suggest a possible association between dermal violaceous change and the use of triamcinolone.

scholarly journals Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis

Lung ◽  
2020 ◽  
Vol 198 (2) ◽  
pp. 395-403 ◽  
Author(s):  
M. Drent ◽  
V. L. J. Proesmans ◽  
M. D. P. Elfferich ◽  
N. T. Jessurun ◽  
S. M. G. de Jong ◽  
...  
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Side Effect ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Future Research ◽  
Dietary Interventions ◽  
Cross Sectional ◽  
Organ Systems ◽  
Gastrointestinal Side Effects

Abstract Background Clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. So far, no curative treatment exists; the disease can only be suppressed. All treatment options cause side effects affecting quality of life. The aim of this study was to establish and rank the prevalence of self-reported gastrointestinal side effects of drugs used in the treatment of sarcoidosis. Methods A cross-sectional web-based anonymous survey about complaints and side effects was conducted among sarcoidosis patients in the Netherlands, United Kingdom, and United States of America. Results Of the participants, 70% were being treated with one or more drugs. The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs). Methotrexate (MTX) users especially experienced nausea, with monotherapy as well as combination therapy. Vomiting and weight loss were most prominent among azathioprine and mycophenolate mofetil (MMF) users, whereas diarrhoea was frequently mentioned by MMF and MTX users. The reported side effects of hydroxychloroquine were generally rather mild. Conclusion The current study ranked the gastrointestinal side effects associated with pharmacotherapy in sarcoidosis patients. Pharmacotherapy does have multiple gastrointestinal side effects. The strongest association between a reported side effect and drug use was that of weight gain associated with increased appetite among prednisone users. It would therefore be useful for future research to look further into dietary interventions to counter these side effects and reduce their burden.

scholarly journals Recent advances in the management of systemic lupus erythematosus

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 970 ◽  
Author(s):  
Savino Sciascia ◽  
Massimo Radin ◽  
Dario Roccatello ◽  
Giovanni Sanna ◽  
Maria Laura Bertolaccini
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Therapeutic Strategies ◽  
Systemic Lupus ◽  
Systemic Involvement ◽  
Phase Ii And Iii ◽  
Chronic Autoimmune Disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible to relapse­ and remission, thus making management challenging. Moreover, a considerable number of side effects may occur with conventional therapies; therefore, there is clearly a need for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from being fully understood. However, greater understanding of the pathways and of the cellular and molecular mediators involved in SLE is being achieved. Emerging evidence has allowed the development of new biological therapeutic options targeting crucial molecular mediators involved in the pathogenesis of SLE. This literature review analyzes the availability of biological and target-directed treatments, phase II and III trials, and new therapies that are being developed for the treatment of SLE.

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Aspartate Aminotransferase ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

scholarly journals The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions

2021 ◽  
Vol 12 ◽  
Author(s):  
Shahin Shams ◽  
Joseph M. Martinez ◽  
John R. D. Dawson ◽  
Juan Flores ◽  
Marina Gabriel ◽  
...  
Keyword(s):  
Biological Sciences ◽  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Treatment Modalities ◽  
Systemic Autoimmune Disease ◽  
Inadequate Response ◽  
Current State ◽  
Therapeutic Landscape ◽  
Socioeconomic Consequences

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical, emotional and socioeconomic consequences. Despite advances in targeted biologic and pharmacologic interventions that have recently come to market, many patients with RA continue to have inadequate response to therapies, or intolerable side effects, with resultant progression of their disease. In this review, we detail multiple biomolecular pathways involved in RA disease pathogenesis to elucidate and highlight pathways that have been therapeutic targets in managing this systemic autoimmune disease. Here we present an up-to-date accounting of both emerging and approved pharmacological treatments for RA, detailing their discovery, mechanisms of action, efficacy, and limitations. Finally, we turn to the emerging fields of bioengineering and cell therapy to illuminate possible future targeted therapeutic options that combine material and biological sciences for localized therapeutic action with the potential to greatly reduce side effects seen in systemically applied treatment modalities.

scholarly journals Virtual Screening of Natural Metabolites as Candidate Drugs for Rheumatoid Arthritis

2020 ◽  
Vol 8 (4S4) ◽  
pp. 226-230
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Virtual Screening ◽  
Membrane Protein ◽  
Drug Target ◽  
Biological Response ◽  
Chemical Compounds ◽  
Novel Drug ◽  
Autodock 4.2

Inflammation is a complex biological response to reject and heal any harmful stimuli created by pathogens, damaged cells or irritants. One of the more prevalent inflammatory disease found in 0.5-1.0% of the world’s population is Rheumatoid arthritis (RA). RA is an autoimmune disease affecting the synovia. The actual reason for this disease is still unknown and is more complex to study. So, the drugs which are commercialized acts only to reduce the outcome of the disease, pain, by inhibiting the vital enzymes responsible for the synthesis of inflammatory mediators called prostaglandins. Cyclooxygenase- I and Cyclooxygenase- II are the commonly targeted enzymes by the current drugs in market. These drugs are reported to affect the normal physiological functions of various organs leading to side effects. PGE2 is the major prostaglandin involved in this disorder and found abundant in the affected synovia. mPGES- I is a membrane protein involved in the biosynthesis of PGE2 which has been reported as a novel drug target to treat RA. Though synthesized chemical compounds have higher anti-inflammatory activity; they are reported to possess a number of side effects. Thus a library of natural compounds are collected and screened virtually as mPGES-1 inhibitors using Autodock 4.2.

scholarly journals Proportion and Factors that Associate with Incidence of Hepatotoxicity in Rheumatoid Arthritis Patients Treated with Methotrexate in RSCM Year 2013−2015

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Rahma Anindya Prathitasari ◽  
Harry Isbagio
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Disease Progression ◽  
Alanine Aminotransferase ◽  
Side Effect ◽  
Normal Limit ◽  
Keywords Rheumatoid Arthritis ◽  
Chronic Autoimmune Disease

Background Rheumatoid arhtirtis (RA) is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate (MTX) which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients' medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60%. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity (p>0.05).Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX. Keywords: Rheumatoid Arthritis, Methotrexate, Hepatotoxicity

scholarly journals Current Pharmaceutical Options for the Treatment of Rheumatoid Arthritis

2019 ◽  
Vol IV (I) ◽  
pp. 1-9
Author(s):  
Sobia Noreen ◽  
Hassan Mahmood ◽  
Ifrah Hussain
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Treatment Goals ◽  
Synovial Lining ◽  
Rheumatoid Arthritis Treatment ◽  
Analgesic Effects ◽  
Persistent Inflammation ◽  
Symptomatic Management ◽  
Organ Systems ◽  
Restricted Mobility

Rheumatoid arthritis is an inflammatory and autoimmune disease that describes the joints persistent inflammation and tendon sheets synovial lining. The primary symptoms of rheumatoid arthritis are stiffness, pain, and swelling of peripheral joints. Persistent inflammation results in many systemic and extra-articular manifestations involving many organ systems. Rheumatoid arthritis treatment goals are symptomatic management of pain, stiffness and restricted mobility. NSAIDs are commonly prescribed for people with rheumatoid arthritis. Analgesic effects of NSAIDs are based mainly on the inhibition of COX-enzyme and consequently the production of prostaglandins.

Sign in / Sign up

Export Citation Format

Share Document